Drug Topics - October 13, 2008 - (Page 3s)

www.drugtopics.com Oct. 13, 2008 Oct. 13, 2008 DRUG TOPICS 3s head_ bylinename_1 T I extdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ textdropcap_ text_ text_ text_ are here to didn’t offer significant clinical adnsulin injections text_ text_ text_ text_ text_ text_ text_ text_ vantage since it used regular insustay. That’s the blunt warning text_ text_ text_ from Jerry Meece, pharmacist, lin,” he said. “And the device was certified diabetes educator, and di- unfortunate. There was no reason subhead_ rector of clinical services at Plaza to carry around a fire extinguishertextnoindent_ textnoindent_ text- sized gadget when there are more Pharmacy and Wellness Center in noindent_ textnoindent_ textnoin- portable alternatives.” Gainesville, Texas. But just because dent_ textnoindent_ textnoindent_ Exubera (inhaled insulin, Pfizer), textnoindent_ textnoindent_on the Needles, pens, pumps the first non-injected insulin textnoindent_ U.S. market, was killed for lack of Those more portable alternatives sales, it does not mean that there are use needles, usually in an insulin text_ text_ text_ text_ text_ text_ text_ text_ text_ syringes and text_ pen. According to a 2008 marno alternatives to text_ text_ vials. text_ text_ pens and pumps are the ket study by information analysis Insulin fastest-growing insulin delivery sys- company RNCOS, pens deliver tems. High-pressure in94 percent of all insulin jectors offer an alternative units in Japan, 86 percent for the needle-phobic. in Europe, and 14 perA bucal spray has been cent in the United States. approved in two coun“We got a late start with tries, and a new inhaled pens,” John Buse, MD, insulin is in Phase III PhD, American Diabetrials. An oral insulin is tes Association president in Phase II trials. “I don’t for medicine and science, John Buse, get too excited until I see said. “Lilly didn’t have MD, PhD evidence that a new delivthe best pens years ago. ery system works in the real world,” Sanofi launched a pen that met Stacy Griffin, diabetes educator and with a good deal of resistance. Now pharmacist at Central Baptist Hos- all the manufacturers have great pital in Lexington, Ky., said. “Even products. And they’re starting to when Exubera was approved, we tell prescribers about them more didn’t jump on it right away.” effectively.” Wall Street was not wowed by Meece said that more inhaled insulin either, Leerink effective marketing is key to Swann diabetes analyst Jonas Alsensas c onver t i n g said. Exubera’s only strength was novelty. “Exubera Fred Gebhart patients. In Europe and Japan, patients with diabetes are commonly treated by care teams that include endocrinologists and pharmacists. Both groups are familiar with delivery op- http://www.drugtopics.com

Table of Contents Feed for the Digital Edition of Drug Topics - October 13, 2008

Drug Topics - October 13, 2008 Contents Latebreakers Letters Kansas Pharmacists Partner with Law Enforcement to Fight Meth Use Pharmacy Board to Oversee Med Distribution at West Virginia Free Clinics Rx Care JP�at Large Celebrating Community Special Report Self-Care Government and Law Newer Treatment Option for Type 2 Diabetes New Products Advertisers Index Technology Classified Viewpoint:�Pharmacists Must Change our Ways

Drug Topics - October 13, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.